Table of Contents Author Guidelines Submit a Manuscript
The Scientific World Journal
Volume 2014, Article ID 948305, 5 pages
http://dx.doi.org/10.1155/2014/948305
Research Article

Preoperative Butyrylcholinesterase Level as an Independent Predictor of Overall Survival in Clear Cell Renal Cell Carcinoma Patients Treated with Nephrectomy

1Department of Urology, Hirosaki University Graduate School of Medicine, Zaifucho 5, Hirosaki 036-8562, Japan
2Department of Anesthesiology, Hirosaki University Graduate School of Medicine, Zaifucho 5, Hirosaki 036-8562, Japan

Received 18 December 2013; Accepted 29 January 2014; Published 4 March 2014

Academic Editors: Z. Akcetin and A. Tefekli

Copyright © 2014 Takuya Koie et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. M. Kozlowski, “Management of distant solitary recurrence in the patient with renal cancer: contralateral kidney and other sites,” Urologic Clinics of North America, vol. 21, no. 4, pp. 601–624, 1994. View at Google Scholar · View at Scopus
  2. R. J. Motzer, N. H. Bander, and D. M. Nanus, “Medical progress: Renal-cell carcinoma,” The New England Journal of Medicine, vol. 335, no. 12, pp. 865–875, 1996. View at Publisher · View at Google Scholar · View at Scopus
  3. M. de Martino, T. klatte, C. Seemann et al., “Validation of serum C-reactive protein (CRP) as an independent prognostic factor for disease-free survival in patients with localised renal cell carcinoma (RCC),” BJU International, vol. 111, no. 8, pp. E348–E353, 2013. View at Google Scholar
  4. S. Steffens, A. Köhler, R. Rudolph et al., “Validation of CRP as prognostic marker for renal cell carcinoma in a large series of patients,” BMC Cancer, vol. 12, pp. 399–406, 2012. View at Google Scholar
  5. S. Brookman-May, M. May, V. Ficarra et al., “Does preoperative platelet count and thrombocytosis play a prognostic role in patients undergoing nephrectomy for renal cell carcinoma? Results of a comprehensive retrospective series,” World Journal of Urology, vol. 31, no. 5, pp. 1309–1316, 2013. View at Google Scholar
  6. J. Du, J. Zheng, X. Chen et al., “High preoperative plasma fibrinogen is an independent predictor of distant metastasis and poor prognosis in renal cell carcinoma,” International Journal of Clinical Oncology, vol. 18, no. 3, pp. 517–523, 2013. View at Google Scholar
  7. M. Trikha, R. Corringham, B. Klein, and J.-F. Rossi, “Targeted anti-interleukin-6 monoclonal antibody therapy for Cancer: a review of the rationale and clinical evidence,” Clinical Cancer Research, vol. 9, no. 13, pp. 4653–4665, 2003. View at Google Scholar · View at Scopus
  8. N. Lampón, E. F. Hermida-Cadahia, A. Riveiro, and J. C. Tutor, “Association between butyrylcholinesterase activity and low-grade systemic inflammation,” Annals of Hepatology, vol. 11, no. 3, pp. 356–363, 2012. View at Google Scholar · View at Scopus
  9. L. Santarpia, L. Alfonsi, F. Pasanisi, C. De Caprio, L. Scalfi, and F. Contaldo, “Predictive factors of survival in patients with peritoneal carcinomatosis on home parenteral nutrition,” Nutrition, vol. 22, no. 4, pp. 355–360, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. A. Chougule, S. Hussain, and D. Agarwal, “Prognostic and diagnostic value of serum pseudocholinesterase, serum aspartate transaminase, and serum alinine transaminase in malignancies treated by radiotherapy,” Journal of Cancer Research and Therapeutics, vol. 4, no. 1, pp. 21–25, 2008. View at Google Scholar · View at Scopus
  11. F. Bozzetti, P. Boracchi, A. Costa et al., “Relationship between nutritional status and tumor growth in humans,” Tumori, vol. 81, no. 1, pp. 1–6, 1995. View at Google Scholar · View at Scopus
  12. S. Mitsunaga, T. Kinoshita, T. Hasebe et al., “Low serum level of cholinesterase at recurrence of pancreatic cancer is a poor prognostic factor and relates to systemic disorder and nerve plexus invasion,” Pancreas, vol. 36, no. 3, pp. 241–248, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. “Urinary Bladder,” in AJCC Cancer Staging Manual, S. B. Edge, D. R. Byrd, C. C. Compton et al., Eds., pp. 497–505, Springer, New York, NY, USA, 7th edition, 2010.
  14. L. Santarpia, I. Grandone, F. Contaldo, and F. Pasanisi, “Butyrylcholinesterase as a prognostic marker: a review of the literature,” Journal of Cachexia, Sarcopenia and Muscle, vol. 4, no. 1, pp. 31–39, 2013. View at Google Scholar
  15. C. Mitrache, J. R. Passweg, J. Libura et al., “Anemia: an indicator for malnutrition in the elderly,” Annals of Hematology, vol. 80, no. 5, pp. 295–298, 2001. View at Publisher · View at Google Scholar · View at Scopus
  16. H. Eggers, C. Seidel, A. J. Schrader et al., “Serum C-reactive protein: a prognostic factor in metastatic urothelial cancer of the bladder,” Medical Oncology, vol. 30, no. 4, pp. 705–711, 2013. View at Google Scholar
  17. S.-Z. Gu, X.-H. Zhao, Q. Ping, S.-B. Li, and B.-R. Pan, “Alterations of serum cholinesterase in patients with gastric cancer,” World Journal of Gastroenterology, vol. 11, no. 29, pp. 4604–4606, 2005. View at Google Scholar · View at Scopus
  18. O. O. Ogunkeye and A. I. Roluga, “Serum cholinesterase activity helps to distinguish between liver disease and non-liver disease aberration in liver function tests,” Pathophysiology, vol. 13, no. 2, pp. 91–93, 2006. View at Publisher · View at Google Scholar · View at Scopus